Base de dados : MEDLINE
Pesquisa : D02.705.400.625.130 [Categoria DeCS]
Referências encontradas : 49 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 5 ir para página              

  1 / 49 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:22310926
[Au] Autor:Roberts MS; Macauley SL; Wong AM; Yilmas D; Hohm S; Cooper JD; Sands MS
[Ad] Endereço:Department of Internal Medicine, Washington University School of Medicine, Campus Box 8007, 660 S. Euclid Ave., St. Louis, MO 63110, USA.
[Ti] Título:Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis.
[So] Source:J Inherit Metab Dis;35(5):847-57, 2012 Sep.
[Is] ISSN:1573-2665
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Infantile neuronal ceroid lipofuscinosis (INCL) is a profoundly neurodegenerative disease of children caused by a deficiency in the lysosomal enzyme palmitoyl protein thioesterase-1 (PPT1). There is currently no effective therapy for this invariably fatal disease. To date, preclinical experiments using single treatments have resulted in incremental clinical improvements. Therefore, we determined the efficacy of CNS-directed AAV2/5-mediated gene therapy alone and in combination with the systemic delivery of the lysosomotropic PPT1 mimetic phosphocysteamine. Since CNS-directed gene therapy provides relatively high levels of PPT1 activity to specific regions of the brain, we hypothesized that phosphocysteamine would complement that activity in regions expressing subtherapeutic levels of the enzyme. Results indicate that CNS-directed gene therapy alone provided the greatest improvements in biochemical and histological measures as well as motor function and life span. Phosphocysteamine alone resulted in only minor improvements in motor function and no increase in lifespan. Interestingly, phosphocysteamine did not increase the biochemical and histological response when combined with AAV2/5-mediated gene therapy, but it did result in an additional improvement in motor function. These data suggest that a CNS-directed gene therapy approach provides significant clinical benefit, and the addition of the small molecule PPT1 mimetic can further increase that response.
[Mh] Termos MeSH primário: Doenças Neurodegenerativas/genética
Doenças Neurodegenerativas/terapia
Lipofuscinoses Ceroides Neuronais/genética
Lipofuscinoses Ceroides Neuronais/terapia
Tioléster Hidrolases/genética
[Mh] Termos MeSH secundário: Animais
Materiais Biomiméticos/farmacologia
Encéfalo/metabolismo
Encéfalo/patologia
Sistema Nervoso Central/patologia
Cistafos/metabolismo
Feminino
Terapia Genética/métodos
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Atividade Motora/genética
Doenças Neurodegenerativas/metabolismo
Doenças Neurodegenerativas/patologia
Lipofuscinoses Ceroides Neuronais/metabolismo
Lipofuscinoses Ceroides Neuronais/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
EC 3.1.2.- (Thiolester Hydrolases); EC 3.1.2.22 (palmitoyl-protein thioesterase); YC9U0409D3 (Cystaphos)
[Em] Mês de entrada:1304
[Cu] Atualização por classe:161019
[Lr] Data última revisão:
161019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120208
[St] Status:MEDLINE
[do] DOI:10.1007/s10545-011-9446-x


  2 / 49 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:12554913
[Au] Autor:Mirdehghan M; Ahmadzadeh A; Bana-Behbahani M; Motlagh I; Chomali B
[Ad] Endereço:Pediatric Nephrology Unit, Abuzar Children's Medical Center, University of Medical Sciences, Ahvaz, Iran. abuzarhosp-library@yahoo.com
[Ti] Título:Infantile cystinosis.
[So] Source:Indian Pediatr;40(1):21-4, 2003 Jan.
[Is] ISSN:0019-6061
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:Ten patients of nephropathic cystinosis were admitted during the period 1995-2000. Their mean age was 12 months. The signs of failure to thrive and advanced rickets were seen in all patients. Other features included polyuria, polydipsia, pathologic fractures and deafness. Laboratory findings included glucosuria, hyposthenuria, hypocalcemia, proteinuria and azotemia. Therapy with phosphocysteamine showed marked clinical improvement.
[Mh] Termos MeSH primário: Acidose Tubular Renal/etiologia
Cistinose/complicações
[Mh] Termos MeSH secundário: Antimetabólitos/uso terapêutico
Consanguinidade
Cistafos/uso terapêutico
Cistinose/tratamento farmacológico
Cistinose/mortalidade
Insuficiência de Crescimento/etiologia
Feminino
Seres Humanos
Lactente
Irã (Geográfico)/epidemiologia
Masculino
Estudos Retrospectivos
Raquitismo/etiologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antimetabolites); YC9U0409D3 (Cystaphos)
[Em] Mês de entrada:0303
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:030130
[St] Status:MEDLINE


  3 / 49 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11283676
[Au] Autor:Zhang Z; Butler JD; Levin SW; Wisniewski KE; Brooks SS; Mukherjee AB
[Ad] Endereço:Section on Developmental Genetics, Heritable Disorders Branch, The National Institute of Child Health and Human Development, The National Institutes of Health, Bethesda, Maryland, USA.
[Ti] Título:Lysosomal ceroid depletion by drugs: therapeutic implications for a hereditary neurodegenerative disease of childhood.
[So] Source:Nat Med;7(4):478-84, 2001 Apr.
[Is] ISSN:1078-8956
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Neuronal ceroid lipofuscinoses (NCLs) are the most common hereditary neurodegenerative diseases of childhood. The infantile form, INCL, is caused by lysosomal palmitoyl-protein thioesterase (PPT) deficiency, which impairs the cleavage of thioester linkages in palmitoylated proteins, preventing their hydrolysis by lysosomal proteinases. Consequent accumulation of these lipid-modified proteins (constituents of ceroid) in lysosomes leads to INCL. Because thioester linkages are susceptible to nucleophilic attack, drugs with this property may have therapeutic potential for INCL. We report here that two such drugs, phosphocysteamine and N-acetylcysteine, disrupt thioester linkages in a model thioester compound, [14C]palmitoyl approximately CoA. Most importantly, in lymphoblasts derived from INCL patients, phosphocysteamine, a known lysosomotrophic drug, mediates the depletion of lysosomal ceroids, prevents their re-accumulation and inhibits apoptosis. Our results define a novel pharmacological approach to lysosomal ceroid depletion and raise the possibility that nucleophilic drugs such as phosphocysteamine hold therapeutic potential for INCL.
[Mh] Termos MeSH primário: Ceroide/metabolismo
Lipofuscinoses Ceroides Neuronais/tratamento farmacológico
Lipofuscinoses Ceroides Neuronais/metabolismo
[Mh] Termos MeSH secundário: Acetilcisteína/farmacologia
Apoptose/efeitos dos fármacos
Células Cultivadas
Criança
Códon sem Sentido
Cistafos/farmacologia
Fibroblastos/efeitos dos fármacos
Fibroblastos/metabolismo
Fibroblastos/patologia
Glicoproteínas/metabolismo
Seres Humanos
Lactente
Linfócitos/efeitos dos fármacos
Linfócitos/metabolismo
Linfócitos/patologia
Lisossomos/efeitos dos fármacos
Lisossomos/metabolismo
Mutação de Sentido Incorreto
Lipofuscinoses Ceroides Neuronais/patologia
Palmitoil Coenzima A/metabolismo
Palmitoil-CoA Hidrolase/deficiência
Palmitoil-CoA Hidrolase/genética
Saposinas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Ceroid); 0 (Codon, Nonsense); 0 (Glycoproteins); 0 (Saposins); 1763-10-6 (Palmitoyl Coenzyme A); EC 3.1.2.2 (Palmitoyl-CoA Hydrolase); WYQ7N0BPYC (Acetylcysteine); YC9U0409D3 (Cystaphos)
[Em] Mês de entrada:0104
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010403
[St] Status:MEDLINE


  4 / 49 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10603127
[Au] Autor:Assadi FK; McCue P; Jefferis S; Shi M; Beckman DA
[Ad] Endereço:Division of Nephrology, Department of Pediatrics, Alfred I. duPont Hospital for Children and Thomas Jefferson University, P.O. Box 269, Wilmington, DE 19899-0269, USA. fassadi@nemours.org
[Ti] Título:Effects of pre- and postnatal cysteamine exposure on renal function in the rat.
[So] Source:Pediatr Nephrol;13(9):812-5, 1999 Nov.
[Is] ISSN:0931-041X
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The safety of cysteamine after renal transplantation and during pregnancy is an important issue, since girls with cystinosis are in better health on cysteamine therapy and thus more likely to become pregnant. In the first study, cysteamine was given to pregnant rats on days 6.5-18.5 post conception in oral doses of 0, 37.5, 75, 100, and 150 mg/kg per day. The dams were sacrificed on day 20.5, the fetal kidneys removed and prepared for histological examination. In the second study, cysteamine was given to dams on days 6.5-19.5 post conception in oral doses of 0, 37.5, 50, and 75 mg/kg per day. Dams were allowed to give birth naturally and pups were given cysteamine on days 4-21 to yield the same oral doses of cysteamine given to the dam. Renal function was evaluated on day 35. Histological examination of fetal kidneys revealed no changes even in kidneys from fetuses with growth retardation and malformations. Furthermore, there were no alterations in renal function in offspring on day 35. These findings demonstrate that cysteamine therapy does not affect renal development in the rat. Further investigations will be required to prove whether cysteamine therapy has the potential to affect renal development in the human.
[Mh] Termos MeSH primário: Cistafos/administração & dosagem
Cisteamina/toxicidade
Rim/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Cistafos/toxicidade
Cisteamina/administração & dosagem
Desenvolvimento Embrionário e Fetal/efeitos dos fármacos
Feminino
Hidrólise
Rim/embriologia
Gravidez
Ratos
Ratos Wistar
Teratogênios/toxicidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Teratogens); 5UX2SD1KE2 (Cysteamine); YC9U0409D3 (Cystaphos)
[Em] Mês de entrada:0002
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:991222
[St] Status:MEDLINE


  5 / 49 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:10073739
[Au] Autor:Tennezé L; Daurat V; Tibi A; Chaumet-Riffaud P; Funck-Brentano C
[Ad] Endereço:Clinical Investigation Centre and Clinical Pharmacology Unit, Saint-Antoine University Hospital, Paris, France.
[Ti] Título:A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers.
[So] Source:Br J Clin Pharmacol;47(1):49-52, 1999 Jan.
[Is] ISSN:0306-5251
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIMS: Cysteamine, the only drug available for the treatment of cystinosis in paediatric patients, is available as the hydrochloride, the bitartrate and as sodium phosphocysteamine salts. It has been suggested that cysteamine bitartrate and phosphocysteamine are better tolerated and may have a better bioavailability than cysteamine hydrochloride. This has, however, never been demonstrated. METHODS: We compared the pharmacokinetics and tolerance of these three formulations of cysteamine in 18 healthy adult male volunteers in a double-blind, latin-square, three-period, single oral dose cross-over relative bioavailability study. RESULTS: No statistical difference was found between relative bioavailabilities, AUC (0, infinity) (geometric mean and s.d. in micromol l(-1) h: 169+/-51, 158+/-46, 173+/-49 with cysteamine hydrochloride, phosphocysteamine and cysteamine bitartrate respectively), Cmax (geometric mean and s.d. in micromol l(-1); 66+/-25.5, 59+/-12, 63+/-20) and tmax (median and range in h: 0.88 (0.25-2), 1.25 (0.25-2), 0.88 (0.25-2)) with each of the three forms of cysteamine tested. Bioequivalence statistics (90% confidence intervals) showed non equivalence of Cmax of cysteamine base as the only non equivalence of pharmacokinetics between the three formulations: 90% CI for Cmax relative ratios to cysteamine hydrochloride were [75.6-105.81 for phosphocysteamine and [74.2-124.2] for cysteamine bitartrate. The only significant adverse event was vomiting whose frequency was inversely correlated with body weight (Spearman's r=-0.76, P<0.001). The nature of the salt tested did not influence vomiting. CONCLUSIONS: While none of the three forms of cysteamine tested has a clear advantage over the others in terms of pharmacokinetics and tolerance profile, this should now however be addressed in patients treated for cystinosis during repeat administrations.
[Mh] Termos MeSH primário: Cistafos/farmacocinética
Cisteamina/farmacocinética
[Mh] Termos MeSH secundário: Adulto
Disponibilidade Biológica
Estudos Cross-Over
Cisteamina/efeitos adversos
Método Duplo-Cego
Seres Humanos
Masculino
Vômito/induzido quimicamente
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
5UX2SD1KE2 (Cysteamine); YC9U0409D3 (Cystaphos)
[Em] Mês de entrada:9906
[Cu] Atualização por classe:140617
[Lr] Data última revisão:
140617
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990312
[St] Status:MEDLINE


  6 / 49 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9438669
[Au] Autor:Fischbach M; Terzic J; Cavalier A; Mambrini P; Geisert J
[Ti] Título:Renal stones in nephropathic cystinosis treated with phosphocysteamine.
[So] Source:Pediatr Nephrol;11(6):787-8, 1997 Dec.
[Is] ISSN:0931-041X
[Cp] País de publicação:Germany
[La] Idioma:eng
[Mh] Termos MeSH primário: Cistafos/efeitos adversos
Cistinose/complicações
Cistinose/tratamento farmacológico
Cálculos Renais/tratamento farmacológico
Protetores contra Radiação/efeitos adversos
[Mh] Termos MeSH secundário: Cistafos/uso terapêutico
Seres Humanos
Lactente
Cálculos Renais/urina
Masculino
Protetores contra Radiação/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Radiation-Protective Agents); YC9U0409D3 (Cystaphos)
[Em] Mês de entrada:9802
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980123
[St] Status:MEDLINE


  7 / 49 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8747105
[Au] Autor:van't Hoff WG; Gretz N
[Ad] Endereço:Medical Unit, Institute of Child Health, London, UK.
[Ti] Título:The treatment of cystinosis with cysteamine and phosphocysteamine in the United Kingdom and Eire.
[So] Source:Pediatr Nephrol;9(6):685-9, 1995 Dec.
[Is] ISSN:0931-041X
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Fifty-nine patients with cystinosis were treated with cysteamine or phosphocysteamine in the United Kingdom up to May 1990. Treatment was started at a median age of 3.2 years (range 0.6-24.8 years) and continued for a median duration of 3.0 years (range 0.01-1.2 years). At the end of the study, 46 (78%) patients remained on treatment. One patient developed end-stage renal failure and 6 died. Efficacy was assessed in the 44 pre-transplant patients. The United Kingdom pre-transplant patients had significantly lower plasma creatinine concentrations at 6 and 8 years than a historical group of patients who did not receive cysteamine (P < 0.0001 and P < 0.0003, respectively). There was no significant difference between pretreatment and final post-treatment height standard deviation scores, suggesting maintenance of growth rate. The leucocyte cystine concentration was less than the accepted upper limit of the treatment range (1 nmol 1/2 cystine/mg protein) in only 21% of determinations. There was no significant difference between the mean pre-treatment and final values of leucocyte cystine concentration. The mean final doses of cysteamine (33 mg/kg per day) and phosphocysteamine (37 mg/kg per day base equivalent) were less than the mean dose (51 mg/kg per day) used in a United States multicentre trial. We conclude that cysteamine treatment was beneficial, but further improvements might be achieved by an improvement in monitoring of therapy.
[Mh] Termos MeSH primário: Cistafos/uso terapêutico
Cisteamina/uso terapêutico
Cistinose/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Cistina/sangue
Cistinose/mortalidade
Cistinose/fisiopatologia
Feminino
Crescimento/efeitos dos fármacos
Seres Humanos
Lactente
Irlanda
Testes de Função Renal
Leucócitos/metabolismo
Masculino
Estudos Retrospectivos
Reino Unido
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
48TCX9A1VT (Cystine); 5UX2SD1KE2 (Cysteamine); YC9U0409D3 (Cystaphos)
[Em] Mês de entrada:9610
[Cu] Atualização por classe:170812
[Lr] Data última revisão:
170812
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:951201
[St] Status:MEDLINE


  8 / 49 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8089624
[Au] Autor:Dragojevic-Simic V; Colic M; Gasic S
[Ad] Endereço:Medical Department, Military Technical Institute, Belgrade, Yugoslavia.
[Ti] Título:Influence of a radioprotector WR-638 on the lymphoid compartment of the irradiated rat thymus: a flow cytometric analysis.
[So] Source:Int J Radiat Biol;66(2):143-50, 1994 Aug.
[Is] ISSN:0955-3002
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The T cell composition of the thymus of X-ray irradiated (3.5 Gy) Wistar rat protected with WR-638 was analyzed by flow cytometry using monoclonal antibodies directed to the Thy 1.1, CD43, CD2, CD5, CD4, CD8 and class I and II MHC antigens. It was shown that this dose of X-rays caused cyclic changes in thymic cellularity manifested as: primary involution (until day 2), primary regeneration (from days 2 to 14), secondary involution (from days 14 to 21) and secondary regeneration (from days 21 to 30). WR-638 reduced the magnitude of thymocyte depletion in the primary involutive phase of the irradiated thymi, primarily as a result of protection of Thy 1.1high+ CD2low+ CD5high+ CD4+ CD8+ class I antigen high+ subpopulations of thymocytes. In the early regenerative phase, WR-638 accelerated the regeneration of CD4-CD8- and CD4-CD8+ thymocyte subsets, followed by subsequent increase of CD4+CD8+ and CD4+CD8- thymocyte subsets. Secondary involutive and regenerative phases in protected animals were characterized by higher absolute cell number of almost all thymocyte subpopulations in comparison with those in irradiated, non-protected animals.
[Mh] Termos MeSH primário: Cistafos/farmacologia
Tecido Linfoide/efeitos dos fármacos
Tecido Linfoide/efeitos da radiação
Timo/efeitos dos fármacos
Timo/efeitos da radiação
[Mh] Termos MeSH secundário: Animais
Anticorpos Monoclonais
Contagem de Células/efeitos dos fármacos
Contagem de Células/efeitos da radiação
Citometria de Fluxo
Masculino
Ratos
Ratos Wistar
Regeneração/efeitos dos fármacos
Regeneração/efeitos da radiação
Subpopulações de Linfócitos T/efeitos dos fármacos
Subpopulações de Linfócitos T/efeitos da radiação
Timo/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); YC9U0409D3 (Cystaphos)
[Em] Mês de entrada:9410
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM; S
[Da] Data de entrada para processamento:940801
[St] Status:MEDLINE


  9 / 49 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8128642
[Au] Autor:Dragojevic-Simic V; Colic M; Gasic S
[Ti] Título:[Radioprotective and therapeutic modulation of thymus gland regeneration in rats after x-ray irradiation].
[Ti] Título:Radioprotektivna i terapijska modulacija regeneracije timusa pacova nakon X-zracenja..
[So] Source:Vojnosanit Pregl;50(5):457-67, 1993 Sep-Oct.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:srp
[Ab] Resumo:There have been studied effects of cystaphos, gammaphos, hydroxyurea, polyadenyl-polyuridinic acids (poly A:poly U) as well as the combination of gammaphos and poly A:poly U, that is, cystaphos and superoxide dismutase on the thymus of Wistar and AO rats irradiated by the hard X-rays in the dose of 5 or 3.5 Gy. Changes were observed up to 30 days after irradiation. The most efficacious protective effect has shown cystaphos (358 mg/kg i.p. 20 min. after irradiation) in Wistar rats irradiated by the dose of 3.5 Gy. It lowered involutive changes and accelerated thymus regeneration. On the basis of phenotypic analysis of thymocytes it can be supposed that such a favourable effect is the consequence of a larger protection of the cortical (strong OX 7+) thymocytes. Differing from cystaphos, transplantation of the syngeneic cells of the bone marrow in AO rats irradiated by the dose of 5 Gy showed favourable effect on thymus regeneration in later phase after irradiation preventing secondary thymus involution.
[Mh] Termos MeSH primário: Protetores contra Radiação/farmacologia
Regeneração
Timo/efeitos da radiação
[Mh] Termos MeSH secundário: Amifostina/farmacologia
Animais
Transplante de Medula Óssea
Cistafos/farmacologia
Hidroxiureia/farmacologia
Masculino
Poli A/farmacologia
Poli U/farmacologia
Ratos
Ratos Wistar
Regeneração/efeitos dos fármacos
Regeneração/efeitos da radiação
Timo/fisiologia
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Radiation-Protective Agents); 24937-83-5 (Poly A); 27416-86-0 (Poly U); M487QF2F4V (Amifostine); X6Q56QN5QC (Hydroxyurea); YC9U0409D3 (Cystaphos)
[Em] Mês de entrada:9404
[Cu] Atualização por classe:150612
[Lr] Data última revisão:
150612
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:930901
[St] Status:MEDLINE


  10 / 49 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:7689384
[Au] Autor:Bakhitova LM; Drobchenko SN
[Ti] Título:[The effect of phenol derivatives on the antimutagenic activity of dextran].
[Ti] Título:Vliianie proizvodnykh fenola na antimutagennuiu aktivnost' dekstrana..
[So] Source:Izv Akad Nauk Ser Biol;(4):613-7, 1993 Jul-Aug.
[Is] ISSN:1026-3470
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The effects of dextran + hydrazine or amino derivative of dibunol and of dextran + cystafos derivatives with different degree of modification of their molecules on the mutagenic activity of gamma irradiation were studied using the micronucleus test in polychromatophilic erythrocytes of the mouse bone marrow. The effects of these compounds on differentiation of the erythroid series has also been studied. The mutagenic activity of gamma irradiation was most markedly inhibited by the copolymer dextran and the amino derivative dibunol. The optimal structure of copolymers was 1 heterocyclic link per 3 non-oxidized links of dextran, while the increasing number of active links in the dextran molecule insignificantly enhanced its antimutagenic effect. The studied compounds effectively protected erythropoiesis.
[Mh] Termos MeSH primário: Antimutagênicos/farmacologia
Dextranos/farmacologia
Fenóis/farmacologia
[Mh] Termos MeSH secundário: Animais
Hidroxitolueno Butilado/farmacologia
Cistafos/farmacologia
Interações Medicamentosas
Eritrócitos/efeitos dos fármacos
Eritrócitos/efeitos da radiação
Eritropoese/efeitos dos fármacos
Eritropoese/efeitos da radiação
Raios gama
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Endogâmicos CBA
Micronúcleos com Defeito Cromossômico/efeitos dos fármacos
Micronúcleos com Defeito Cromossômico/efeitos da radiação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antimutagenic Agents); 0 (Dextrans); 0 (Phenols); 1P9D0Z171K (Butylated Hydroxytoluene); YC9U0409D3 (Cystaphos)
[Em] Mês de entrada:9309
[Cu] Atualização por classe:161123
[Lr] Data última revisão:
161123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:930701
[St] Status:MEDLINE



página 1 de 5 ir para página              
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde